Specifications
Small molecule-induced protein degradation is an attractive strategy for the development of chemical probes. Protein degraders have the power to abrogate all of the functions of a drug target at once, including scaffolding functions which are difficult to target with small molecule inhibitors. A novel class of PROTACs that incorporate small molecule VHL ligands to successfully degrade HaloTag7 fusion proteins is developed. HaloPROTACs will inspire the development of future PROTACs with more drug-like properties. In HEK 293 cells stably expressing GFP-HaloTag7, 24 hour treatment with HaloPROTAC1 leads to less than 20% degradation, the longer HaloPROTAC2 leads to nearly 70% degradation of GFP-Halotag7 at 2.5 μM. HaloPROTACs containing protein degrader 1 leads to nearly 70% degradation of GFP-HaloTag7, when sufficiently long linkers are used. Derivative of the von Hippel-Lindau (VHL) ligand, VH 032, commonly used as a precursor to PROTACs that hijack VHL as the E3 ubiquitin ligase component. Supplied with a primary amine functional handle at a position known not to significantly affect binding to VHL, for ready conjugation to a linker/target protein ligand.
Product Information:
Purity: >98%MW: 467.02Formula: C22H31ClN4O3SCAS No. 1448189-80-7Physical State: Lyophilized white powderQuantity: 5 mg; 10 mg; 25 mgSolubility: 40 mg/mL in DMSOStorage: Store desiccated as supplied at -20°C for up to 3 years. Store solutions at -80°C for up to 6 months or -20°C for up to 1 month.
References
1. Buckley DL et al. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. ACS Chem Biol. 2015 Aug 21;10(8):1831-7.2. Zengerle et al (2015) Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem.Biol. 10 1770 PMID: 260356253. Galdeano et al (2014) Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J.Med.Chem. 57 8657
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
阴性对照(Isotype Control):非特异荧光的强弱取决于抗体浓度、单克隆荧光抗体特异性和纯度,应与试验管抗体相对应。在多色分析时,同型对照应与其它抗体同时使用,以避免补偿造成的误差
血小板体外活化试验:使用正常人活化标本作为阳性质控;使用正常人未活化标本作为阴性质控
血小板自身抗体检测:使用含有已知血小板抗体的血清与血小板孵育,作为阳性质控;使用不含血小板抗体的血清与血小板孵育,作为阴性质控
血小板表面抗原缺失:如巨血小板症血小板表面CD42a/CD42b缺失,血小板无力症血小板表面gpIIb/IIIa,即CD41/CD61缺失或异常。使用正常人标本做阳性对照,抗体的同型对照做阴性对照
英 ['aɪsətaɪp]美 ['aɪsəˌtaɪp]
n.
同型动物(或植物),图形文字,象征性图像;同位型;同模;同号模式
网络
同型;同种型;模式标本
双语例句
Study on the Action of Decreasing level of Isotype Cysteine for High Blood Viscosity
降低同型半胱氨酸水平对高黏血症作用的研究
其同型为;percp-cy5.5(25ug包装)浓度:0.2mg/ml,
那么如果CD45RA抗体如果加入20ul,那同型抗体应该加入多少ml:
我自己的初步计算是:1ul的3分之1.不知道我算对了吗?应该怎么加才好呢?
英 ['aɪsətaɪp]美 ['aɪsəˌtaɪp]
n. 同型动物(或植物),图形文字,象征性图像;同位型;同模;同号模式
暂无品牌问答